ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review Article   
  • cpb,
  • DOI: 10.4172/2167-065X.1000289

The Major Role of Probiotics as a Mitigation Strategy against Coronavirus Disease

Vishnu Suppiramaniam*
Department of Pharmacal Sciences, Auburn University, USA
*Corresponding Author : Vishnu Suppiramaniam, Department of Pharmacal Sciences, Auburn University, USA, Email: Vishnu_Suppiramaniam@gmail.com

Received Date: Sep 01, 2022 / Accepted Date: Sep 29, 2022 / Published Date: Sep 29, 2022

Abstract

Scientists are working to identify forestalment/ treatment styles and clinical issues of coronavirus complaint 2019 (COVID- 19). Nutritive status and diet have a major impact on the COVID- 19 complaint process, substantially because of the bidirectional commerce between gut microbiota and lung, that is, the gut – lung axis. Individualities with shy nutritive status have a pre-existing imbalance in the gut microbiota and impunity as seen in rotundity, diabetes, hypertension and other habitual conditions.

Citation: Suppiramaniam V (2022) The Major Role of Probiotics as a Mitigation Strategy against Coronavirus Disease. Clin Pharmacol Biopharm, 11: 289. Doi: 10.4172/2167-065X.1000289

Copyright: © 2022 Suppiramaniam V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top